PFE 8-K Current Reports

PFIZER INC 8-K Report, Financial Results (Aug 4, 2026)

Pfizer reported second-quarter 2026 results on August 4, 2026, showing revenues of $15.0 billion, up 3% reported and 1% operationally, with Adjusted diluted EPS of $0.77 (flat year over year). Growth was narrow: excluding Comirnaty and Paxlovid, revenues rose 5% operationally, and products the company classifies as Launched and Acquired grew 18%. Reported results were a loss of $(0.04) per share, driven by $4.3 billion in non-cash intangible asset impairments (chiefly $3.8 billion on sigvotatug vedotin's Phase 3 lung cancer IPR&D asset after unfavorable trial results, and $525 million on Oxbryta) and a $1.9 billion gain from selling the ViiV Healthcare stake, which was offset by higher legal charges. Management raised the midpoint of full-year 2026 revenue guidance by $500 million to $60.5-$62.5 billion, citing about $1.5 billion of better-than-expected non-COVID performance, partly offset by a cut in COVID-19 product revenue expectations to about $4 billion from $5 billion. Adjusted diluted EPS guidance of $2.80-$3.00 was reaffirmed, but it absorbs roughly $0.10 from a $650 million acquired IPR&D charge tied to the Innovent Biologics licensing deal, which closed July 10, 2026 and will be recorded in Q3 2026. The company also expanded its cost programs with about $2.5 billion of additional net savings expected from 2027 through 2029, against roughly $2.0 billion of one-time costs for the cost realignment initiative, and an additional $1.5 billion of COGS savings with about $4.0 billion in one-time costs. Total net savings targets now reach about $6.7 billion (cost realignment) and $3.0 billion (manufacturing optimization). Leadership changes and capital allocation are also in focus. CFO Dave Denton departs August 15, 2026, and Cecile Guegan becomes Interim CFO on August 16 during a search for a permanent successor. Pfizer paid $4.9 billion in dividends ($0.86 per share) in the first half and made no share repurchases in 2026, with $3.3 billion of authorization remaining. Management said it is prioritizing reinvestment and de-leveraging, and the guidance assumes no buybacks.

Aug 4, 2026 8-K

PFIZER INC 8-K Report, Executive Changes (Jun 18, 2026)

Pfizer Inc. (PFE) disclosed in an 8-K filed June 18, 2026 that Chief Financial Officer Dave Denton will step down effective August 15, 2026 to take a consumer goods role outside the pharmaceutical industry. The company states the departure is not related to its financial or operating results, or to any disagreements over financial, operational, accounting, or reporting policies or practices. This is a leadership transition rather than a change in reported financial performance, and the filing contains no financial results, guidance changes, or quantitative disclosures. Cecile Guegan, Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer from August 16, 2026, while Pfizer conducts a comprehensive internal and external search for a permanent successor. Ms. Guegan, 55, joined Pfizer in 2005 and has held her current role since 2022, with prior finance leadership positions including Vice President, Finance, Research & Development and Business Office from 2020 to 2022. She is directly responsible for the financial operations and reporting of Pfizer's biopharmaceutical business, and she led finance integration of Seagen in 2024. Mr. Denton and Ms. Guegan will work together to ensure a seamless handover, which mitigates near-term execution risk. For investors, the key items to monitor are the timing and profile of the permanent CFO hire, any change in capital allocation or guidance tone under new leadership, and whether the transition affects the integration of recent large transactions the CEO cited, including Seagen, Biohaven, and Metsera. The filing describes the change as orderly and unrelated to accounting or performance concerns, but a CFO vacancy during an ongoing search carries some uncertainty until a permanent appointment is made.

Jun 18, 2026 8-K

Regulation FD

PFIZER INC 8-K Report, Regulation FD Disclosure (Jun 18, 2026)

Pfizer Inc. (PFE) filed an 8-K on June 18, 2026, primarily to reaffirm its previously issued fiscal year 2026 financial guidance following the announcement of a Chief Financial Officer transition. The company reiterated its revenue guidance of $59.5 billion to $62.5 billion and its Adjusted Diluted Earnings Per Share (EPS) guidance of $2.80 to $3.00. This reaffirmation suggests that despite the executive change, Pfizer's management remains confident in the company's operational and financial outlook for the remainder of the fiscal year. Investors should note that this filing does not introduce new financial targets but rather confirms existing ones, providing a degree of stability amidst organizational adjustments. The extensive risk factors included in the filing underscore the inherent volatility and uncertainties associated with the pharmaceutical industry.

Jun 18, 2026 8-K

PFIZER INC 8-K Report, Financial Results (May 5, 2026)

Pfizer (PFE) reported first-quarter 2026 results on May 5, 2026, with total revenues of $14.5 billion, up 5% reported and 2% operationally. Excluding the steep declines in COVID-19 products Comirnaty and Paxlovid, revenue grew 7% operationally, and revenues from the company's Launched and Acquired Products rose 22%. Reported diluted EPS was $0.47, down 10% year over year, while Adjusted diluted EPS was $0.75, down 18% from $0.92. The earnings decline was driven by higher cost of sales (reflecting the non-recurrence of a prior-year royalty accrual revision), higher R&D spending, a higher effective tax rate, and a sharp drop in Adjusted EPS relative to the prior year, partly offset by lower SI&A expenses. Pfizer reaffirmed all components of its full-year 2026 guidance, including revenues of $59.5 to $62.5 billion and Adjusted diluted EPS of $2.80 to $3.00. Guidance embeds an anticipated approximately $1.5 billion unfavorable revenue impact from generic and biosimilar competition and assumes no share repurchases in 2026. Management highlighted strong growth in Padcev, Eliquis, Nurtec, Lorbrena and oncology biosimilars, and pipeline momentum including positive Phase 3 readouts for Braftovi, Elrexfio and Talzenna, a Phase 2 readout for atirmociclib, and an encouraging Phase 2 result for tilrekimig. The Lyme disease vaccine candidate missed its first pre-specified statistical criterion, a notable setback. Capital allocation remained focused on reinvestment and the dividend: Pfizer invested $2.5 billion in internal R&D, paid $2.4 billion in dividends ($0.43 per share), and completed no share buybacks in the quarter. Additional items of note include the completed exit of its ViiV Healthcare stake for $1.875 billion (about $1.65 billion net cash, to be recognized in Q2 2026), and April settlements extending U.S. Vyndamax patent protection to June 1, 2031, which management says should keep revenues relatively stable through mid-2031 rather than declining from 2029.

May 5, 2026 8-K

PFIZER INC 8-K Report, Shareholder Vote Results (Apr 27, 2026)

Pfizer Inc. (PFE) held its Annual Meeting of Shareholders on April 23, 2026, with the key outcomes being the election of its Board of Directors and the ratification of its independent auditor. All nominated directors received a substantial majority of "For" votes, indicating strong shareholder confidence in the current leadership. Additionally, the selection of KPMG LLP as the independent registered public accounting firm for fiscal year 2026 was overwhelmingly approved. Shareholders also approved the amended Pfizer Inc. 2019 Stock Plan and, on an advisory basis, the compensation of the Named Executive Officers. However, a shareholder proposal to adopt an Independent Chair Policy was not approved, signaling that the majority of shareholders prefer the current board structure. These outcomes reflect a generally supportive shareholder base for Pfizer's governance and executive compensation practices.

Apr 27, 2026 8-K

Regulation FDExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Feb 3, 2026)

Pfizer reported fourth-quarter and full-year 2025 results on February 3, 2026, with full-year revenues of $62.6 billion, down 2% reported and operationally, but up 6% operationally excluding Paxlovid and Comirnaty. Full-year reported diluted EPS was $1.36, versus $1.41 in 2024, while adjusted diluted EPS rose 4% to $3.22. Fourth-quarter reported results were a loss of $(0.29) per share, driven largely by $4.4 billion of non-cash intangible asset impairments (including about $3.6 billion of IPR&D, such as $1.6 billion for disitamab vedotin), while adjusted diluted EPS grew 5% to $0.66 and fourth-quarter revenues fell 1% to $17.6 billion. Management reaffirmed 2026 guidance of $59.5 to $62.5 billion in revenues and $2.80 to $3.00 in adjusted diluted EPS. The guidance embeds roughly $5 billion of COVID-19 product revenue, a roughly $1.5 billion headwind from loss of exclusivity, and the anticipated impact of Most-Favored-Nation pricing and TrumpRx. No share repurchases are assumed for 2026, and none were made in 2025, leaving $3.3 billion of authorization remaining. Dividends totaled $9.8 billion, or $1.72 per share, in 2025. The filing highlights a heavy investment phase: $8.8 billion in business development in 2025, mainly the Metsera acquisition and the 3SBio in-license, and about 20 planned key pivotal study starts in 2026. Investors will weigh these pipeline and obesity bets against near-term earnings pressure, the rising impairment charges, and the $1.875 billion cash exit from the ViiV stake expected in Q1 2026.

Feb 3, 2026 8-K

PFIZER INC 8-K Report, Regulation FD Disclosure (Dec 16, 2025)

On December 16, 2025, Pfizer issued Exhibit 99.1 providing full-year 2026 guidance and revising its full-year 2025 revenue guidance, while reaffirming all other components of its 2025 financial outlook. The company revised 2025 revenue guidance to approximately $62.0 billion, down from the prior $61.0–$64.0 billion range set on November 4, 2025, and reaffirmed 2025 Adjusted diluted EPS of $3.00–$3.15. Pfizer guided 2026 revenues to $59.5–$62.5 billion, with COVID-19 product revenue falling from roughly $6.5 billion to about $5.0 billion and approximately $1.5 billion of negative impact from loss of exclusivity (LOE) products. Management expects roughly 4% operational revenue growth at the midpoint in 2026 excluding COVID-19 and LOE products. The 2026 earnings outlook is weaker than 2025. Adjusted diluted EPS is guided to $2.80–$3.00, versus $3.00–$3.15 for 2025, driven mainly by lower expected revenues and a higher effective tax rate on Adjusted income of about 15%, up from about 11%. Combined 2026 Adjusted SI&A and R&D spending is expected at $23.0–$25.0 billion, reflecting continued cost realignment and increased R&D investment, including the in-licensed PD-1 x VEGF bispecific antibody from 3SBio and Metsera clinical programs. Guidance excludes business development deals not completed as of December 16, 2025, assumes about 5.74 billion diluted shares, and assumes no share repurchases in 2025 or 2026. For investors, the key takeaways are the lower 2025 revenue outlook, a 2026 year that absorbs post-LOE and COVID-related declines, and a step-up in R&D investment that pressures near-term EPS. The filing is furnished under Regulation FD rather than filed, and the forward-looking statements carry substantial risk disclosed in Pfizer's SEC filings.

Dec 16, 2025 8-K

PFIZER INC 8-K Report, Corporate Update (Nov 21, 2025)

Pfizer Inc. (PFE) announced the successful completion of a significant public offering of various debt securities on November 21, 2025. The offering comprised an aggregate principal amount of $6.75 billion across multiple tranches, including Floating Rate Notes due 2027 and fixed-rate notes maturing between 2027 and 2065 with coupon rates ranging from 3.875% to 5.700%. This substantial capital raise was executed under Pfizer's existing shelf registration statement. This offering indicates Pfizer's proactive approach to managing its capital structure and potentially funding ongoing operations, research and development, or strategic initiatives. The diverse maturity dates and interest rate structures of the notes suggest a strategy to diversify its debt profile and optimize borrowing costs. Investors should note the total size of the issuance and the specific terms of each note series to understand Pfizer's current debt obligations and its financial strategy.

Nov 21, 2025 8-K

Other Events

PFIZER INC 8-K Report, Corporate Update (Nov 13, 2025)

Pfizer Inc. announced the successful completion of its acquisition of Metsera, Inc. for an enterprise value of approximately $7.0 billion. This strategic move signifies Pfizer's expansion into the obesity and metabolic disease market, a key growth area. The acquisition was executed through a merger agreement, with Metsera shareholders receiving $65.60 in cash per share at closing. In addition to the upfront cash payment, Metsera shareholders are eligible to receive contingent value rights (CVRs) worth up to an additional $20.65 per share. These CVRs are tied to the achievement of specific developmental and regulatory milestones related to Metsera's pipeline, notably its GLP-1 receptor antagonist and amylin analog drug candidates. Investors should closely monitor the progress of MET-097i and MET-233i, as their successful advancement could represent significant future value creation for Pfizer.

Nov 13, 2025 8-K

PFIZER INC 8-K Report, Financial Results (Nov 4, 2025)

Pfizer reported third-quarter 2025 results on November 4, 2025 that were mixed on the top line but solid on earnings. Revenues were $16.7 billion, down 6% reported and down 7% operationally, driven by a steep decline in COVID-19 products (Paxlovid down 55% operationally, Comirnaty down 20%). Excluding COVID-19 products, the non-COVID portfolio grew 4% operationally, led by Eliquis (up 22% operationally), Nurtec ODT/Vydura (up 22%), and Vyndaqel family (up 7%). Reported diluted EPS fell 21% to $0.62, reflecting a one-time $1.35 billion acquired IPR&D charge tied to the 3SBio in-licensing deal, while Adjusted diluted EPS was $0.87, down 18% year over year. Management reaffirmed full-year 2025 revenue guidance of $61.0 to $64.0 billion and raised and narrowed Adjusted diluted EPS guidance to $3.00 to $3.15, up from $2.90 to $3.10. The EPS increase was supported by year-to-date performance, cost-reduction progress, and an improved effective tax rate assumption of about 11%, down from 13%. Management also highlighted a landmark agreement with the U.S. government on drug pricing and tariff relief, and early FTC clearance for the pending Metsera acquisition, which has since been contested by a competing Novo Nordisk proposal. For investors, the key tensions are the structural erosion of COVID-19 revenue, the pressure from upcoming generic and biosimilar competition, and the capital allocation trade-off. Pfizer has paid $7.3 billion in dividends, has made no share repurchases in 2025, and is guiding to none. Management is prioritizing de-leveraging while keeping room for business development, including the Metsera deal, which is expected to be financed with cash and new debt.

Nov 4, 2025 8-K

PFIZER INC 8-K Report, Financial Results (Aug 5, 2025)

Pfizer reported second-quarter 2025 results on August 5, 2025, with revenues of $14.7 billion, up 10% on an operational basis, driven by strong growth in Vyndaqel family, Comirnaty, Paxlovid, Padcev, Abrysvo, and Lorbrena, partially offset by Ibrance declines and higher IRA-related Medicare Part D manufacturer discounts. Reported diluted EPS was $0.51 versus $0.01 a year earlier, while Adjusted diluted EPS rose 30% to $0.78. Reported results benefited from net gains on equity securities and lower interest expense, and Pfizer's cost discipline showed through lower SI&A (down 8%) and R&D (down 8%) spending. Management reaffirmed full-year 2025 revenue guidance of $61.0 to $64.0 billion and raised Adjusted diluted EPS guidance by $0.10 at the midpoint to $2.90 to $3.10. The raise absorbs a one-time approximately $0.20 EPS charge from a $1.35 billion acquired IPR&D charge tied to the 3SBio licensing agreement, which will be recorded in Q3 2025. The guidance also reflects a lower assumed effective tax rate of approximately 13% (previously 15%) and reduced SI&A and R&D expense ranges, and it absorbs tariff impacts and potential pricing changes following a July 31, 2025 letter from President Trump. Capital allocation remains focused on de-leveraging and reinvestment. Pfizer paid $4.9 billion in dividends in the first half of 2025 and has made no share repurchases this year, with guidance assuming none for the full year, leaving $3.3 billion of remaining authorization. The company also reiterated its target of approximately $7.2 billion in net cost savings by the end of 2027. Investors should note the Q3 3SBio charge, continued pressure from IRA pricing and generic/biosimilar erosion, and the reliance on COVID-19 products whose demand remains seasonal and uncertain.

Aug 5, 2025 8-K

Earnings & ResultsFinancial EventsExhibits & Filings

PFIZER INC 8-K Report, Corporate Update (May 19, 2025)

Pfizer Inc. (PFE) announced through its wholly-owned Dutch subsidiary, Pfizer Netherlands International Finance B.V., the successful completion of a substantial public offering of senior unsecured notes. The offering, totaling €3.25 billion across four tranches with varying maturities and interest rates, was made under a previously established shelf registration statement. This debt issuance represents a strategic move by Pfizer to raise capital, likely for general corporate purposes, potential acquisitions, or to refinance existing debt. The fully and unconditionally guaranteed nature of the notes by Pfizer Inc. provides investors with direct recourse to the parent company, enhancing the security of their investment. Investors should note the specific coupon rates and maturity dates for each tranche of notes, which indicate the cost of borrowing for Pfizer over different time horizons.

May 19, 2025 8-K

PFIZER INC 8-K Report, Financial Results (Apr 29, 2025)

Pfizer reported solid first-quarter 2025 results on April 29, 2025, with revenues of $13.7 billion, down 8% reported (6% operationally) from $14.9 billion a year earlier, largely due to a roughly $1.5 billion decline in Paxlovid. Reported diluted EPS was $0.52 versus $0.55, while Adjusted diluted EPS rose 12% to $0.92 from $0.82, supported by lower SI&A and R&D spending and a low Adjusted tax rate of 7.8%. Pfizer reaffirmed all components of its 2025 guidance, including revenues of $61.0 to $64.0 billion and Adjusted diluted EPS of $2.80 to $3.00, and said it is trending toward the upper end of the EPS range. Guidance excludes any impact from future tariff changes. The more consequential news is the expansion of the cost realignment program. Pfizer now expects total net cost savings of about $5.7 billion through 2027, comprising the previously stated $4.5 billion by end-2025 plus about $1.2 billion of additional SI&A savings, with one-time costs of about $1.6 billion. A separate R&D reorganization is expected to yield about $500 million in savings by end-2026, to be reinvested in the pipeline, at a one-time cost of about $600 million. Investors should weigh these savings against roughly $2.2 billion in total incremental one-time charges, which will weigh on GAAP results over the coming years, and note that the savings are measured against a 2023 baseline and are subject to execution risk. Capital allocation remains focused on the dividend ($2.4 billion paid in the quarter, $0.43 per share) and deleveraging, with gross leverage now below the company's target. No share repurchases have been made in 2025, and guidance assumes none. Pfizer has $3.3 billion remaining on its repurchase authorization and retains flexibility for business development. Pfizer also fully exited its Haleon stake, generating roughly $3.3 billion in March after roughly $3.0 billion in January.

Apr 29, 2025 8-K

PFIZER INC 8-K Report, Shareholder Vote Results (Apr 28, 2025)

Pfizer Inc. (PFE) filed an 8-K on April 27, 2025, detailing the outcomes of its Annual Meeting of Shareholders held on April 24, 2025. The primary focus of the filing is the shareholder votes on several key proposals. Importantly, all director nominees presented were elected to the Board of Directors, indicating continued shareholder confidence in the current leadership. Furthermore, shareholders ratified the selection of KPMG LLP as Pfizer's independent registered public accounting firm for the fiscal year 2025, a standard procedure that suggests no major concerns regarding the company's auditors.

Apr 28, 2025 8-K

Regulation FDExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Feb 4, 2025)

Pfizer reported fourth-quarter and full-year 2024 results on February 4, 2025, with full-year revenues of $63.6 billion, up 7% operationally, and fourth-quarter revenues of $17.8 billion, up 21% operationally. The headline growth is flattered by a one-time $3.5 billion Paxlovid revenue reversal in fourth-quarter 2023, so the cleaner signal is the 12% operational growth in non-COVID products for the full year. Full-year reported diluted EPS was $1.41 and adjusted diluted EPS was $3.11, while fourth-quarter reported EPS was $0.07 and adjusted EPS was $0.63, the latter depressed by $2.9 billion of non-cash intangible asset impairments. Management reaffirmed all components of 2025 guidance: revenues of $61.0 to $64.0 billion and adjusted diluted EPS of $2.80 to $3.00. The company raised its cost realignment savings target to approximately $4.5 billion by the end of 2025 and expects to earn $1.5 billion of net savings from the first phase of its Manufacturing Optimization Program by 2027. Guidance assumes about $0.6 billion of revenue erosion from generic and biosimilar competition and no share repurchases in 2025, as Pfizer prioritizes deleveraging following the $43.4 billion Seagen acquisition. Capital allocation remains constrained: no buybacks were executed in 2024, dividends totaled $9.5 billion, and internal R&D spending was $10.8 billion. Pfizer expects to de-lever sufficiently by year-end 2025 to shift toward a more balanced capital allocation strategy, which could include business development or renewed buybacks. Recent pipeline news was mixed, with positive Phase 3 results for Braftovi (BREAKWATER) and sasanlimab (CREST), offset by a Phase 3 DMD program discontinuation and impairment charges. Pfizer also sold about 700 million Haleon shares for roughly $3.0 billion in January 2025, reducing its stake from roughly 15% to 7%.

Feb 4, 2025 8-K

PFIZER INC 8-K Report, Regulation FD Disclosure (Dec 17, 2024)

Pfizer issued its full-year 2025 guidance on December 17, 2024 and reaffirmed its October 29, 2024 guidance for 2024. For 2025 it expects revenue of $61.0 to $64.0 billion and Adjusted diluted EPS of $2.80 to $3.00. Against a 2024 baseline that excludes about $1.2 billion of non-recurring Paxlovid revenue and about $0.30 of non-recurring EPS benefit, management projects roughly flat to 5% operational revenue growth and 10% to 18% operational Adjusted EPS growth. The 2025 revenue outlook already reflects a roughly $1 billion net headwind from Medicare Part D redesign under the Inflation Reduction Act and about $0.6 billion of generic and biosimilar competition. The guidance rests on continued cost discipline. Pfizer says it has achieved its goal of $4.0 billion in net operating expense savings through 2024 under its cost realignment program and expects an additional $500 million in 2025. It projects 2025 Adjusted SI&A plus R&D expenses of $24.0 to $26.0 billion, and it expects initial net savings from the first phase of its Manufacturing Optimization Program in late 2025, aimed at gross margin improvement. Guidance assumes about 5.74 billion diluted shares and no share repurchases in 2024 or 2025, and it excludes any business development deals not completed by December 16, 2024. Investors should note the optical nature of much of the 2025 EPS growth. The 2024 base is flattered by one-time items, and 2025 loses Haleon equity income from Adjusted earnings after Pfizer reduced its Haleon stake in Q4 2024. Adjusted EPS guidance also assumes a higher effective tax rate of about 15%, compared with about 13% in 2024. The release is furnished under Regulation FD rather than filed, and the detailed presentation is available on Pfizer's investor website.

Dec 17, 2024 8-K

PFIZER INC 8-K Report, Financial Results (Oct 29, 2024)

Pfizer reported third-quarter 2024 results on October 29, 2024, with revenues of $17.7 billion, up 31% reported and 32% operationally year-over-year, and raised full-year 2024 guidance for both revenue ($61.0 to $64.0 billion, previously $59.5 to $62.5 billion) and Adjusted diluted EPS ($2.75 to $2.95, previously $2.45 to $2.65). The headline growth is flattered by Paxlovid ($2.7 billion, including a one-time $442 million Strategic National Stockpile delivery) and the year-over-year comparison against a $5.6 billion non-cash inventory write-off in Q3 2023. Management emphasized that excluding Paxlovid and Comirnaty, revenues grew 14% operationally, and that legacy Seagen, Vyndaqel, Eliquis, Xtandi and Nurtec were the main contributors, while Xeljanz and Ibrance declined. GAAP Reported diluted EPS was $0.78 for the quarter, compared with a loss of $0.42 a year earlier. Adjusted diluted EPS was $1.06. Reported results benefited from a much lower cost of sales, which fell 43% to 29.7% of revenues, but were offset by a $420 million charge tied to the expected sale of a facility after Pfizer discontinued its Duchenne muscular dystrophy program, along with higher net interest expense from the Seagen financing. Management reiterated a target of at least $5.5 billion in net cost savings from its cost initiatives, including at least $4 billion by year-end 2024. Capital returns were $7.1 billion in dividends for the first nine months, with no share repurchases year-to-date and none assumed in guidance. For investors, the key questions are the sustainability of COVID-product revenue after 2024, the pace of non-COVID growth, and whether the cost program produces the promised margin expansion. The filing also notes the October 2024 sale of Haleon shares for about $3.5 billion, which reduces Pfizer's stake from roughly 23% to 15%, and the voluntary withdrawal of Oxbryta, which reduces sickle cell sales. The earnings release is furnished under Item 2.02 and is not deemed filed for Section 18 purposes.

Oct 29, 2024 8-K

PFIZER INC 8-K Report, Executive Changes (Oct 15, 2024)

Pfizer's 8-K reports the election of Mortimer J. "Tim" Buckley to its Board of Directors, effective immediately, following the Board's election on October 10, 2024. The Board made the appointment after a search that began in May 2024. Mr. Buckley was also named to the Governance & Sustainability Committee and the Audit Committee. Following his appointment, the Board has 14 directors, 13 of whom are independent. The filing contains no financial results, guidance, or material financial events. Mr. Buckley receives an indemnification agreement and compensation under Pfizer's standard non-employee director arrangements. The filing does not disclose the specific compensation amounts. His addition to the Audit Committee is the most notable governance detail for investors, since it adds a director with extensive investment management and financial markets experience to oversight of financial reporting. Mr. Buckley, age 55, previously served as Chairman and CEO of Vanguard from 2018 until his retirement in 2024. Earlier at Vanguard, he was Chief Investment Officer, overseeing internally managed stock, bond, and money market portfolios, and he held other senior roles, including Chief Information Officer. He also chaired the Children's Hospital of Philadelphia board from 2011 to 2017. Overall, this is a routine board refresh with modest direct investment impact, though it strengthens the Board's financial and capital markets expertise.

Oct 15, 2024 8-K

Leadership ChangesOther EventsExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Jul 30, 2024)

Pfizer reported second-quarter 2024 results on July 30, 2024, with revenues of $13.3 billion, up 2% reported and 3% operationally year-over-year. Growth was modest on a headline basis because Comirnaty revenue fell 87% operationally, but excluding Comirnaty and Paxlovid, revenues grew 14% operationally, driven by legacy Seagen oncology products, Vyndaqel, Eliquis, and Nurtec. This was the first year-over-year topline revenue growth since the fourth quarter of 2022, when COVID revenues peaked. Reported GAAP diluted EPS was just $0.01, versus $0.41 a year earlier, reflecting a $1.3 billion one-time restructuring charge for the new Manufacturing Optimization Program, a $1.1 billion swing in other deductions (including net equity securities losses and higher net interest expense), and a 130.2% effective tax rate. Adjusted diluted EPS was $0.60, down 11% from $0.67. Management raised full-year 2024 guidance to revenues of $59.5–62.5 billion (up $1 billion at the midpoint) and Adjusted diluted EPS of $2.45–2.65 (up $0.30 at the midpoint), with the effective tax rate on Adjusted income lowered to about 13% from 15%. For investors, the key takeaways are the underlying strength of the non-COVID portfolio, the roughly $1.5 billion of expected manufacturing savings by 2027 against about $1.7 billion of one-time costs, and continued dividend payments of $4.8 billion in the first half with no share repurchases planned for 2024. Pipeline setbacks included the failed CIFFREO Phase 3 trial of fordadistrogene movaparvovec for Duchenne muscular dystrophy and a $240 million related impairment, while the giroctocogene fitelparvovec hemophilia A Phase 3 study succeeded.

Jul 30, 2024 8-K

PFIZER INC 8-K Report, Executive Changes (Jul 26, 2024)

Pfizer (PFE) filed an 8-K on July 26, 2024 disclosing that its Compensation Committee, on July 24, 2024, approved modifications to outstanding 2022 and 2023 Five-Year Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) for up to approximately 9,000 active employees, including named executive officers Albert Bourla, David M. Denton, Mikael Dolsten, Aamir Malik, Angela Hwang and Douglas M. Lankler. The changes are voluntary: eligible holders may elect to extend TSRU terms by two years (2022 grants settling in February 2029 instead of 2027; 2023 grants in February 2030 instead of 2028), with vesting moved to the fifth anniversary of grant. For PSAs, participants may elect to extend the three-year performance period by two years, with 2022 awards now settling in 2027 instead of 2025 and 2023 awards in 2028 instead of 2026. Management attributes the move to retention concerns after COVID-era grant prices were set at record highs and the stock has since declined. For investors, the key points are the extended vesting and settlement timelines, which defer potential dilution and cash or share settlement of these awards, and the retention rationale, which signals management's concern about talent retention amid share price weakness. The PSA changes also tighten some features: the operating goal range is 0%-200%, the relative TSR modifier is capped at 25 percentage points, and payouts are capped at target if TSR is negative over the period. Death-related settlement terms are also updated, consistent with 2024 grants. The filing does not quantify the accounting charge, incremental expense, or share count impact, so investors should look to the Schedule TO tender offer documents for those details. The program is structured as a tender offer (the Modification Offer) that had not yet commenced at filing, so final terms, participation rates, and financial effects remain to be confirmed. Investors should monitor the Schedule TO filing and any subsequent disclosures on participation levels and associated compensation expense.

Jul 26, 2024 8-K

Leadership Changes

PFIZER INC 8-K Report, Executive Changes (Jul 10, 2024)

Pfizer Inc. (PFE) has announced a significant leadership transition within its Research & Development division. Dr. Mikael Dolsten, the Chief Scientific Officer and President of Pfizer Research & Development, is initiating a search for his successor after a commendable 15-year tenure. This development signals a potential shift in the strategic direction or operational focus of Pfizer's crucial R&D efforts. Dr. Dolsten is expected to remain with the company in his current capacity until a successor is identified and a smooth transition is facilitated, with a commitment to stay through at least February 28, 2025. Investors should closely monitor the selection process for Dr. Dolsten's replacement, as the new appointee will play a vital role in shaping Pfizer's future drug pipeline and innovation strategy. The company's ability to attract top talent for this critical role will be a key indicator of its ongoing commitment to scientific advancement and long-term growth.

Jul 10, 2024 8-K

PFIZER INC 8-K Report, Executive Changes (Jul 1, 2024)

Pfizer Inc. (PFE) filed an 8-K on July 1, 2024 to disclose the election of Cyrus Taraporevala to its Board of Directors, effective immediately. The board elected him on June 27, 2024, and he will join both the Audit Committee and the Compensation Committee. He receives an indemnification agreement and standard non-employee director compensation. The filing is governance-focused and does not disclose any financial results, guidance, or material operational changes. Taraporevala, age 57, brings substantial investment management experience. He was President and CEO of State Street Global Advisors from 2017 until his retirement in 2022, and previously held leadership roles at Fidelity, BNY Mellon, Legg Mason, and Citigroup, as well as a partnership at McKinsey & Company. He also sits on the boards of Shell plc and Bridgepoint Group plc. Chairman and CEO Albert Bourla framed the appointment as adding investment management and financial markets expertise to the board. For investors, the appointment is a routine board refresh with modest direct financial impact. Its relevance lies in the Audit Committee seat, given his finance background, and the Compensation Committee role, which may bear on executive pay oversight. Investors may also note that his other public company board roles could affect his time commitments, though the filing does not raise concerns about this.

Jul 1, 2024 8-K

Financial Events

PFIZER INC 8-K Report, Exit or Disposal Costs (May 22, 2024)

Pfizer Inc. has announced a multi-year program aimed at reducing its cost of goods sold (COGS), a significant initiative for improving operational efficiency and profitability. The first phase of this program, focusing on operational efficiencies, is projected to yield approximately $1.5 billion in savings by the end of 2027, with some benefits anticipated to materialize starting in 2025. This cost-reduction effort will require an estimated $1.7 billion in one-time costs, primarily for severance and implementation expenses. These charges are expected to be recognized in 2024, with the majority of the cash outlays occurring in 2025 and 2026. Investors should note that these figures are estimates and subject to various assumptions, with actual results potentially differing. The company also cautions that future phases or unforeseen events could lead to additional charges.

May 22, 2024 8-K

PFIZER INC 8-K Report, Financial Results (May 1, 2024)

Pfizer reported first-quarter 2024 results on May 1, 2024, with revenues of $14.9 billion, down 20% reported and 19% operationally from $18.5 billion a year earlier. The decline was driven by a steep drop in COVID-19 products: Comirnaty revenues fell 88% operationally to $354 million and Paxlovid fell 50% to $2.0 billion. Excluding those two products, revenues grew 11% operationally to $12.5 billion, supported by legacy Seagen contributions ($742 million), Vyndaqel family growth (up 66%), Eliquis (up 10%), Abrysvo, and Prevnar family (up 7%). Reported diluted EPS was $0.55 (down 44%), and Adjusted diluted EPS was $0.82 (down 33%). Both figures include a $0.11 favorable one-time impact from a $771 million Paxlovid revenue reversal adjustment. Management reaffirmed full-year 2024 revenue guidance of $58.5 to $61.5 billion and raised Adjusted diluted EPS guidance to $2.15 to $2.35, up from $2.05 to $2.25. The company remains on track for at least $4 billion in net cost savings by year-end 2024 under its cost realignment program. Guidance assumes roughly 90% of Comirnaty sales occur in the second half, largely in the fourth quarter, reflecting COVID vaccine seasonality. Capital returned to shareholders included $2.4 billion in dividends ($0.42 per share), with no share repurchases made in 2024 to date and none anticipated under current guidance. For investors, the key takeaways are the strength of the non-COVID portfolio and the margin benefit from lower COVID product mix, offset by higher net interest expense following the Seagen acquisition and a sharp decline in total reported revenue. The quarter's reported GAAP results were weighed down by amortization, interest costs, and legal and Haleon-related items, so Adjusted measures paint a more favorable picture than GAAP figures.

May 1, 2024 8-K

PFIZER INC 8-K Report, Shareholder Vote Results (Apr 29, 2024)

Pfizer Inc. (PFE) filed an 8-K report detailing the outcomes of its Annual Meeting of Shareholders held on April 25, 2024. The report primarily focuses on shareholder voting results for various proposals, including the election of directors, ratification of its independent auditor, and advisory votes on executive compensation. All incumbent director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board's leadership and governance. The selection of KPMG LLP as the independent registered public accounting firm for fiscal year 2024 also received substantial approval. Furthermore, shareholders voted in favor of the Amended and Restated Pfizer Inc. 2019 Stock Plan and approved, on an advisory basis, the compensation of the company's Named Executive Officers, signaling general agreement with the company's incentive structures and remuneration policies.

Apr 29, 2024 8-K

PFIZER INC 8-K Report, Financial Results (Jan 30, 2024)

Pfizer reported fourth-quarter and full-year 2023 results on January 30, 2024, showing sharp year-over-year declines driven by the expected fall in COVID-19 revenues. Full-year 2023 revenues were $58.5 billion, down 42% reported (41% operationally), while revenues excluding Comirnaty and Paxlovid grew 7% operationally. Reported diluted EPS was $0.37, down 93%, and Adjusted diluted EPS was $1.84, down 72%. Results were heavily affected by one-time items: $5.6 billion of COVID product inventory write-offs in Q3 2023 and a $3.5 billion non-cash Paxlovid revenue reversal in Q4 2023, which together reduced EPS by $1.36 for the full year. Fourth-quarter Reported diluted EPS was a loss of $(0.60), with Adjusted diluted EPS of $0.10. The quarter also featured the completion of the $43 billion Seagen acquisition in December 2023, which Pfizer positions as the foundation of a new world-class oncology business. Management highlighted a record nine new molecular entity approvals from the FDA in 2023 and strong growth from newer and in-line products such as Abrysvo, Vyndaqel family, and Eliquis. Pfizer reaffirmed its 2024 guidance of $58.5 to $61.5 billion in revenue and Adjusted diluted EPS of $2.05 to $2.25. That EPS range includes a roughly $0.40 dilution from Seagen, mainly financing costs, and assumes no share repurchases. For investors, the key questions are whether non-COVID growth (targeted at 8% to 10% operationally in 2024 including Seagen) can offset the continued COVID revenue decline, whether the cost realignment program delivers at least $4 billion in net savings by end-2024, and how the company manages its increased debt load after the Seagen financing. The dividend was $1.64 per share for 2023, and the company has $3.3 billion remaining on its repurchase authorization but does not plan to use it in 2024.

Jan 30, 2024 8-K

Acquisitions & DispositionsRegulation FDExhibits & Filings

PFIZER INC 8-K Report, Corporate Update (Jan 10, 2024)

Pfizer (PFE) disclosed in this 8-K, filed with a press release dated January 10, 2024, that it received notice of an unsolicited "mini-tender" offer from TRC Capital Investment Corporation to buy up to 4,000,000 shares of common stock at $27.35 per share in cash. The offer price is about 4.4% below the $28.61 closing price on December 27, 2023, the business day before the offer date. The targeted shares represent roughly 0.071% of shares outstanding, so the financial exposure to Pfizer and its shareholders is minimal and the filing contains no operational, financial-performance, or guidance information. Pfizer states it does not endorse the offer and recommends that shareholders not tender. It also states it is not affiliated with TRC Capital, its offer, or its offer documents. The company's position is that the below-market price and numerous conditions make the offer unattractive. Shareholders who have already tendered may withdraw their shares at any time before expiration. The offer is scheduled to expire at 12:01 a.m. New York City time on January 30, 2024, though TRC Capital may extend it at its discretion. For investors, the practical takeaway is that this is a routine, low-materiality disclosure. The main risk is to uninformed holders who might tender shares at a discount to market, since mini-tender offers are exempt from many SEC protections that apply to larger tender offers. Pfizer urges shareholders to check current market quotations and consult a broker or financial advisor before responding to any such offer.

Jan 10, 2024 8-K/A

PFIZER INC 8-K/A Report, Acquisition Completed (Dec 14, 2023)

On December 14, 2023, Pfizer completed its acquisition of Seagen Inc. through a merger in which Merger Sub was merged into Seagen, leaving Seagen as a wholly owned Pfizer subsidiary. Each Seagen share was converted into the right to receive $229.00 in cash, and Pfizer described the deal as a total enterprise value of approximately $43 billion. Seagen's outstanding equity awards were either cashed out at the merger consideration, based on achievement of applicable performance metrics, or converted into Pfizer cash-based awards on substantially the same terms. Strategically, the deal significantly expands Pfizer's oncology franchise. Seagen contributes a leading antibody-drug conjugate (ADC) platform and four marketed medicines: ADCETRIS, PADCEV, TIVDAK and TUKYSA. Pfizer says its oncology portfolio now includes more than 25 approved medicines and biosimilars across more than 40 indications, and that its oncology pipeline has roughly doubled to 60 programs. Management characterized oncology as a likely significant growth driver that will contribute meaningfully to Pfizer's near- and long-term financial goals. The filing does not quantify revenue contribution, earnings impact, synergies, or the financing used. To address U.S. Federal Trade Commission concerns, Pfizer irrevocably donated the U.S. royalty rights on Bavencio (avelumab) sales to the American Association for Cancer Research. The filing also notes that this document is Amendment No. 1 on Form 8-K/A, filed solely to correct the EDGAR submission header, which had referred to Item 2.02 instead of Item 2.01. The disclosures themselves are unchanged from the original report.

Dec 14, 2023 8-K

Earnings & ResultsRegulation FDExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Dec 14, 2023)

On December 14, 2023, Pfizer completed its acquisition of Seagen Inc. under the Merger Agreement dated March 12, 2023. Seagen became a wholly owned subsidiary of Pfizer, and each Seagen share was converted into the right to receive $229.00 in cash, with equity awards either settled at the same price (adjusted for performance metrics and tax withholding) or converted into Pfizer cash-based awards on substantially similar terms. Pfizer described the transaction as a total enterprise value of approximately $43 billion, one of the largest investments in the company's history, and a major push into oncology. Strategically, the deal gives Pfizer Seagen's antibody-drug conjugate (ADC) platform and four in-line medicines: ADCETRIS, PADCEV, TIVDAK and TUKYSA. Pfizer says its oncology portfolio now includes over 25 approved medicines and biosimilars across more than 40 indications, with nine medicines that are blockbusters or have blockbuster potential, and that its oncology pipeline has roughly doubled to 60 programs. Management expects oncology to become a significant growth driver and a meaningful contributor to its near- and long-term financial goals. A regulatory condition also applies. To address Federal Trade Commission concerns, Pfizer irrevocably donated the U.S. royalty rights to sales of Bavencio (avelumab) to the American Association for Cancer Research. Investors should weigh the large purchase price and integration risk against the expected growth from the ADC franchise. The filing and press release note risks including failure to realize anticipated benefits, integration difficulties, unknown liabilities, and uncertainty around commercial success and pipeline outcomes.

Dec 14, 2023 8-K

Regulation FDExhibits & Filings

PFIZER INC 8-K Report, Regulation FD Disclosure (Dec 13, 2023)

Pfizer issued full-year 2024 guidance on December 13, 2023, furnished under Item 7.01 (Regulation FD) as Exhibit 99.1. The company guides to 2024 revenues of $58.5 to $61.5 billion, which includes roughly $3.1 billion from the Seagen acquisition, about $1 billion from reclassifying royalty income into revenue, and approximately $8 billion from Comirnaty and Paxlovid. Excluding COVID products and Seagen, operational revenue growth is guided at 3% to 5%; including Seagen but excluding COVID products, growth is 8% to 10%. Adjusted diluted EPS guidance is $2.05 to $2.25, down from the 2023 guidance range of $1.45 to $1.65 shown in the table. That figure is not a like-for-like decline: the legacy Pfizer 2024 range is $2.45 to $2.65, and the Seagen transaction carries a $0.40 dilutive impact, mainly from financing costs. Adjusted SI&A plus R&D expenses are expected to be $24.8 to $26.8 billion, and the cost realignment program now targets at least $4.0 billion in annual net savings, $500 million more than previously expected. For investors, the key takeaways are that Seagen's contribution and the cost program are central to 2024 earnings, while the reported EPS decline and the dependence on COVID franchises (Comirnaty and Paxlovid) are the main risks. The guidance assumes about 5.75 billion diluted shares, no share repurchases, and mid-November 2023 exchange rates. The company also said Seagen regulatory approvals were received and closing was expected on December 14, 2023.

Dec 13, 2023 8-K

Leadership ChangesRegulation FDExhibits & Filings

PFIZER INC 8-K Report, Executive Changes (Dec 12, 2023)

Pfizer announced on December 12, 2023 that the HSR waiting period for its acquisition of Seagen expired on December 11, 2023, and that all required regulatory approvals are now in hand. Pfizer now expects to close the roughly pending Seagen merger on December 14, 2023, subject to other customary closing conditions. To address FTC concerns, Pfizer will irrevocably donate U.S. royalty rights on Bavencio (avelumab) to the American Association for Cancer Research, a move that removes a potential regulatory obstacle without, per the filing, a disclosed material financial impact. Alongside the closing, Pfizer is reorganizing its commercial operations effective January 1, 2024. A new Pfizer Oncology Division, combining oncology commercial and R&D operations from Pfizer and Seagen, will be led by Dr. Chris Boshoff as Chief Oncology Officer. Non-oncology commercial operations will be split into a Pfizer U.S. Commercial Division (led by Aamir Malik) and a Pfizer International Commercial Division (led by Alexandre de Germay, who is joining from outside Pfizer). The role of Chief Commercial Officer held by Angela Hwang is being eliminated, effective December 15, 2023. She will receive severance under the Executive Severance Plan, plus retirement-related benefits, and will serve as an advisor to the CEO during the transition. For investors, the key near-term items are deal closing timing, the leadership restructuring that accompanies the integration, and the company's full-year 2024 financial guidance, which management will provide on a call on December 13, 2023. The filing itself does not quantify the financial impact of the reorganization or the Hwang severance. Forward-looking risks flagged include the possibility of failing to realize expected deal benefits, integration difficulties, transaction costs, and the potential for unexpected costs from reorganization.

Dec 12, 2023 8-K

Earnings & ResultsFinancial EventsRegulation FD+1

PFIZER INC 8-K Report, Financial Results (Oct 31, 2023)

Pfizer reported third-quarter 2023 revenue of $13.2 billion, down 42% from the prior-year quarter, as expected declines in COVID-19 products (Paxlovid down 97% and Comirnaty down 70% operationally) drove a 41% operational decline. Excluding those two products, company revenue grew 10% operationally, led by Abrysvo, Vyndaqel family, Prevnar family, and the recently acquired Nurtec ODT/Vydura and Oxbryta. Reported diluted loss per share was $(0.42) and adjusted diluted loss per share was $(0.17), both hit by a $5.6 billion non-cash inventory write-off and other charges that reduced EPS by $0.84. Reported net loss was $(2.4) billion versus net income of $8.6 billion a year earlier. Pfizer reaffirmed full-year 2023 guidance of $58.0 to $61.0 billion in revenue and $1.45 to $1.65 in adjusted diluted EPS. The company also reaffirmed its 6% to 8% non-COVID operational revenue growth target. Guidance continues to include a one-time non-cash revenue reversal of about $4.2 billion tied to the expected return of 7.9 million EUA-labeled Paxlovid treatment courses to the U.S. government, plus the $5.6 billion charge. Management expects the company's cost realignment program, targeting at least $3.5 billion in annual net savings by 2024, to improve operating margins. For investors, the key issues are the sharp drop in COVID-19 revenue, the earnings impact of one-time charges, and whether the non-COVID portfolio and cost savings can offset the decline. Pfizer also continues to pursue its proposed Seagen acquisition, which received unconditional EC antitrust clearance during the quarter. The company did not repurchase shares in 2023 and does not anticipate doing so in its guidance.

Oct 31, 2023 8-K

PFIZER INC 8-K Report, Financial Results (Oct 13, 2023)

Pfizer's October 13, 2023 8-K reports a sharp reset of 2023 guidance driven by COVID products. Full-year 2023 revenue guidance falls to $58.0-$61.0 billion from $67.0-$70.0 billion, and Adjusted diluted EPS guidance falls to $1.45-$1.65 from $3.25-$3.45. The cuts come mainly from Paxlovid and Comirnaty: Paxlovid revenue is reduced by about $7.0 billion, including a non-cash $4.2 billion reversal tied to the return of roughly 7.9 million EUA-labeled treatment courses, and Comirnaty revenue is reduced by about $2.0 billion on lower-than-expected vaccination rates. Pfizer also recorded a $5.5 billion non-cash charge in Q3 2023, mostly for Paxlovid inventory write-offs ($4.6 billion), with the remainder for Comirnaty. The amended U.S. government Paxlovid agreement removes a major uncertainty by setting a path to commercialization on January 1, 2024. Under the deal, the government returns unused EUA inventory in exchange for a credit that funds a patient assistance program, and Pfizer will supply 1.0 million courses to the Strategic National Stockpile. Commercial sales to privately insured patients will begin in 2024 at negotiated prices, and revenue will be recognized as product is delivered. Management says non-COVID products remain on track for 6-8% operational growth in 2023. The company also launched a multi-year enterprise-wide cost realignment program targeting at least $3.5 billion in savings ($1.0 billion in 2023, at least $2.5 billion in 2024) at one-time costs of about $3.0 billion, mostly cash. The $1.0 billion of 2023 savings partly offsets the guidance cut, and Pfizer expects to incorporate the program into 2024 guidance. Key risks for investors include continued uncertainty around COVID demand, the pace of the commercial transition, and whether the savings and restructuring costs play out as estimated.

Oct 13, 2023 8-K

PFIZER INC 8-K Report, Financial Results (Aug 1, 2023)

Pfizer reported second-quarter 2023 revenues of $12.7 billion, down 54% year over year, as COVID-19 products Paxlovid and Comirnaty collapsed from their pandemic-era peak. Excluding those two products, revenues grew 5% operationally, and management pointed to a second-half acceleration in non-COVID growth driven by a dense slate of launches. Reported diluted EPS was $0.41 (down 77%) and Adjusted diluted EPS was $0.67 (down 67%), reflecting the revenue decline, higher SI&A and R&D spending, and a sharply negative effective tax rate of (3.1)% from global tax resolutions. The company narrowed its full-year 2023 revenue guidance to $67-70 billion from $67-71 billion and cut its non-COVID operational growth expectation to 6-8% from 7-9%, citing short-term headwinds such as a restricted Talzenna label, a CDC shared-decision-making recommendation for Abrysvo, and tornado damage at its Rocky Mount, N.C. sterile injectables plant. Adjusted EPS guidance of $3.25-3.45 was maintained. Pfizer also disclosed that it completed a $31 billion debt offering to finance the pending Seagen acquisition, which it expects to close in late 2023 or early 2024, and that no share repurchases have been made in 2023. For investors, the key questions are the pace of COVID product transition to commercial markets in the second half, whether the launch cadence offsets the loss of COVID revenue, and how quickly leverage from the Seagen financing is reduced. The filing itself is a routine earnings furnishing under Item 2.02 and does not contain new material events beyond the reported results and guidance update.

Aug 1, 2023 8-K

Leadership Changes

PFIZER INC 8-K Report, Executive Changes (Jul 27, 2023)

Pfizer Inc. announced a significant restructuring of its Research and Development (R&D) organization, strategically elevating Oncology to a standalone unit. This move is directly linked to Pfizer's planned future investments in oncology, including the proposed acquisition of Seagen Inc. The new structure aims to enhance focus and agility within its cancer drug development pipeline. As part of this reorganization, Dr. Mikael Dolsten, Chief Scientific Officer and President of Pfizer R&D, will oversee consolidated early and late-stage development, while Dr. Chris Boshoff transitions to Chief Oncology Research and Development Officer. Importantly, Dr. William Pao, the former Chief Development Officer, will be leaving the company effective August 15, 2023, due to the elimination of his role. His departure is classified as an involuntary termination without cause, triggering specific severance and equity acceleration provisions as outlined in his employment agreements and company plans.

Jul 27, 2023 8-K

PFIZER INC 8-K Report, Corporate Update (May 19, 2023)

Pfizer Inc. (PFE) has announced the completion of a substantial public offering totaling $30 billion in aggregate principal amount across eight different note issuances, ranging from 2025 to 2063 maturities and carrying interest rates between 4.450% and 5.340%. These notes are fully and unconditionally guaranteed by Pfizer Inc. on a senior unsecured basis. The primary purpose of this significant debt issuance is to finance a portion of the consideration for Pfizer's proposed acquisition of Seagen Inc. An important detail for investors is the conditional nature of the debt utilization. If the Seagen acquisition does not close by a specified date (or if Pfizer decides not to pursue it), a Special Mandatory Redemption will be triggered for most of the notes (excluding the 2033 and 2053 Notes). In such an event, these redeemed notes will be repurchased at 101% of their principal amount plus accrued interest. The proceeds from the 2033 and 2053 Notes, however, would be available for general corporate purposes, potentially including existing debt obligations.

May 19, 2023 8-K

Other Events

PFIZER INC 8-K Report, Corporate Update (May 15, 2023)

This 8-K filing from Pfizer Inc. (PFE) provides an update on the pending acquisition of Seagen Inc. The key information for investors is that Pfizer and Seagen have submitted their respective notification and report forms under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act. This is a necessary step in the regulatory approval process for the merger. While the filing confirms the HSR submission, it does not offer any new financial data or significant strategic shifts. Investors should note that the closing of the merger remains contingent on several factors, including the expiration or termination of the HSR waiting period and potential approval from the European Commission (EC) if the merger is referred for review. The timing of these regulatory approvals will be a critical determinant of when the Seagen acquisition will be completed and when Pfizer can begin to realize the anticipated benefits of this transaction.

May 15, 2023 8-K

PFIZER INC 8-K Report, Financial Results (May 2, 2023)

Pfizer's first-quarter 2023 results (reported May 2, 2023) showed revenues of $18.3 billion, down 29% reported and 26% operationally, as expected declines in Comirnaty (COVID-19 vaccine) sales drove the drop. Comirnaty revenue fell 75% operationally to roughly $3.1 billion in direct sales and alliance revenues, while Paxlovid rose to $4.1 billion, helping combined COVID-19 product revenue reach $7.1 billion. Excluding these two products, company revenues grew 5% operationally, led by Nurtec ODT/Vydura, Oxbryta, Eliquis and Vyndaqel, partly offset by a 33% operational decline in Xeljanz. Reported diluted EPS was $0.97 (down 29%) and Adjusted diluted EPS was $1.23 (down 24%). Pfizer reaffirmed all components of its full-year 2023 guidance, including revenues of $67.0 to $71.0 billion and Adjusted diluted EPS of $3.25 to $3.45. Management expects the majority of its 7% to 9% operational growth (excluding COVID-19 products) to occur in the second half of 2023, when a series of anticipated product launches is expected. The guidance midpoint implies a steep decline from 2022 driven by lower COVID-19 revenue, with Comirnaty guided to about $13.5 billion and Paxlovid to about $8 billion. The guidance assumes no share repurchases in 2023. The filing also highlights the pending $43 billion acquisition of Seagen, financed largely through $31 billion of new long-term debt, with closing expected in late 2023 or early 2024. Management noted that the company will de-lever after the deal closes and expects its balance sheet to continue supporting dividend increases and future business development. Investors should weigh the near-term earnings pressure and dependence on COVID-19 product sales against the company's launch pipeline and the leverage that the Seagen transaction will add.

May 2, 2023 8-K

Material AgreementsRegulation FDOther Events+1

PFIZER INC 8-K Report, Shareholder Vote Results (May 1, 2023)

Pfizer Inc. (PFE) filed a Form 8-K on May 1, 2023, detailing the outcomes of its Annual Meeting of Shareholders held on April 27, 2023. The report indicates strong shareholder support for the election of all director nominees and the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year 2023. Additionally, shareholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers and opted for an annual frequency for future advisory votes on executive compensation. However, the filing also reveals that several shareholder proposals did not receive majority support. These include proposals related to termination pay ratification, adopting an independent board chairman policy, requesting feasibility reports on IP transfer for COVID-19 manufacturers, examining the impact of extended patent exclusivities on product access, and reporting on political contributions congruency. The overwhelming majority of votes against these proposals suggests that the Board's recommendations were largely followed by shareholders.

May 1, 2023 8-K

PFIZER INC 8-K Report, Material Agreement (Mar 13, 2023)

Pfizer (NYSE: PFE) announced on March 12–13, 2023 a definitive merger agreement to acquire Seagen Inc. (Nasdaq: SGEN) for $229 per share in cash, a total enterprise value of approximately $43 billion inclusive of net debt. The price represents a 33% premium to the March 10, 2023 closing price and a 42% premium to the unaffected price on February 24, 2023. The deal is structured as a merger of Pfizer's wholly owned subsidiary Aris Merger Sub into Seagen, with Seagen surviving as a wholly owned Pfizer subsidiary. Both boards unanimously approved the transaction, and Baker Bros. Advisors, which controls roughly 46 million Seagen shares, signed a voting agreement to support it. For investors, the central strategic rationale is that Seagen brings a leading antibody-drug conjugate (ADC) platform, four approved cancer medicines, and a pipeline of roughly eleven new molecular entities. Seagen expects about $2.2 billion in 2023 revenue (12% growth), and Pfizer believes it could contribute more than $10 billion in risk-adjusted revenue by 2030. Pfizer plans to fund the deal mainly with about $31 billion of new long-term debt, with the remainder from short-term financing and existing cash. Management expects the deal to be neutral to slightly accretive to adjusted diluted EPS in the third to fourth full year after closing, with nearly $1 billion in cost efficiencies targeted by the third full year. The key risks are regulatory and deal-completion risks. Closing requires Seagen stockholder approval, HSR clearance, and certain non-U.S. antitrust and foreign investment approvals. Seagen would owe Pfizer a termination fee of about $1.65 billion in specified circumstances, including a superior proposal, while Pfizer would owe Seagen about $2.22 billion if antitrust or foreign investment rules block the deal. The outside date is March 12, 2024, extendable to September 12, 2024. Closing is expected in late 2023 or early 2024. Investors should also note that the Pfizer-side revenue projections are described as subject to clinical and regulatory success.

Mar 13, 2023 8-K

Other Events

PFIZER INC 8-K Report, Corporate Update (Feb 21, 2023)

Pfizer Inc. (PFE) has officially relocated its corporate headquarters as of February 21, 2023. The new address is 66 Hudson Boulevard East, New York, NY 10001-2192. This relocation signifies a potential strategic move for the company, possibly reflecting changes in operational needs, talent acquisition strategies, or a desire to be in a more centralized or modern business hub. While the physical address change is the primary event disclosed, investors should consider the broader implications of such a move, which can sometimes be associated with significant operational adjustments, lease agreements, and potential impacts on employee logistics. It is important to note that this filing does not disclose any financial performance details or strategic shifts related to the relocation itself. The telephone number for Pfizer remains unchanged, indicating that core communication channels are unaffected. Investors seeking to understand the financial or operational ramifications of this headquarters move should look for further disclosures or interpret it within the context of Pfizer's overall business strategy and ongoing operational updates.

Feb 21, 2023 8-K

PFIZER INC 8-K Report, Financial Results (Jan 31, 2023)

Pfizer reported record full-year 2022 results, with revenues of $100.3 billion (up 23% reported, up 30% operationally) and reported diluted EPS of $5.47 (up 42%). Adjusted diluted EPS was $6.58 (up 62%). Growth was driven overwhelmingly by COVID-19 products, notably Paxlovid and Comirnaty. Excluding those two products, full-year revenue grew only 2% operationally, which is the key nuance for investors. Fourth-quarter revenue was $24.3 billion (up 2% reported, 13% operational), and Q4 adjusted diluted EPS was $1.14 (up 45%). Q4 also benefited from a $0.32 per-share boost from lower acquired IPR&D expense versus the prior-year quarter. The central message is the 2023 guidance, which points to a sharp decline. Management guided to revenues of $67.0 to $71.0 billion, a roughly 29% to 33% decline, and adjusted diluted EPS of $3.25 to $3.45, a roughly 48% to 51% decline. The drop reflects expected COVID-19 revenue falling about 64% for Comirnaty (to ~$13.5 billion) and 58% for Paxlovid (to ~$8 billion). Management also guided to 7% to 9% operational growth excluding COVID-19 products, and to roughly $2.8 billion of incremental SI&A and R&D investment to support launches and pipeline programs. Guidance is subject to significant uncertainty, particularly around SARS-CoV-2 strain severity and infection rates, and assumes no share repurchases in 2023. Pipeline and regulatory news was extensive, with multiple FDA and EMA decisions expected through 2023 and 2024, including RSVpreF, Prevnar 20 pediatric, etrasimod, and the MenABCWY vaccine. Management frames these launches as the basis for growth through the decade. Capital deployment in 2022 included roughly $26 billion in business development, led by the Biohaven, Arena, and GBT acquisitions, alongside $9.0 billion in dividends ($1.60 per share).

Jan 31, 2023 8-K

Corporate Changes

PFIZER INC 8-K Report, Bylaw Amendment (Dec 13, 2022)

Pfizer Inc. (PFE) has filed an 8-K report detailing amendments to its corporate bylaws, effective December 9, 2022. The primary change addresses shareholder proxy solicitations for director nominations, specifically aligning with Rule 14a-19 of the Securities Exchange Act of 1934, commonly known as the "universal proxy rules." These amendments are designed to enhance transparency and compliance in the director nomination and election process, particularly in contested proxy solicitations. For investors, this update signifies a procedural adjustment rather than a change in the company's financial performance or strategic direction. The core implication is that shareholders seeking to nominate directors will need to adhere to stricter disclosure and solicitation requirements, including providing evidence of compliance with the universal proxy rules. This aims to ensure a more standardized and informative voting process for all shareholders, especially in situations involving multiple director candidates.

Dec 13, 2022 8-K

PFIZER INC 8-K Report, Financial Results (Nov 1, 2022)

Pfizer reported third-quarter 2022 revenues of $22.6 billion, down 6% reported and down 2% operationally, as the prior-year quarter was inflated by exceptionally strong COVID-19 demand. Excluding Paxlovid and Comirnaty, revenues grew 2% operationally. Reported diluted EPS was $1.51 (up 6%), including a $0.15 benefit from multi-year tax resolutions, and Adjusted diluted EPS was $1.78 (up 40%, or 44% excluding FX). Nine-month revenues rose 32% to $76.0 billion, reflecting the COVID-19 product ramp. Management raised the low end of full-year 2022 revenue guidance to $99.5-$102.0 billion, with Comirnaty guidance lifted by $2 billion to about $34 billion and Paxlovid reaffirmed at about $22 billion. Adjusted diluted EPS guidance was raised and narrowed to $6.40-$6.50. The company also flagged a $0.19 EPS headwind from its new policy of expensing all acquired IPR&D within Adjusted results, and guidance does not assume further share repurchases in 2022. The quarter also featured the closing of the Biohaven (about $12.8 billion total upfront) and Global Blood Therapeutics (about $5.6 billion) acquisitions in early Q4, which expand the company's CGRP migraine and sickle cell franchises. Pipeline news included positive Phase 3 readouts for RSVpreF, Prevnar 20 in pediatrics, Talzenna/Xtandi, and a pentavalent meningococcal vaccine, with management citing up to 19 new products or indications over the next 18 months. Investors should weigh the strong near-term COVID-driven EPS against the underlying Biopharma softness, the elevated acquisition spending, and the dependence on Comirnaty and Paxlovid, whose revenues are expected to decline as the pandemic recedes.

Nov 1, 2022 8-K

Regulation FDOther EventsExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Jul 28, 2022)

Pfizer reported second-quarter 2022 revenues of $27.7 billion, up 47% reported and 53% on an operational basis, driven primarily by Paxlovid ($8.1 billion) and Comirnaty (up 20% operationally). Reported diluted EPS rose 77% to $1.73, and Adjusted diluted EPS rose 92% to $2.04. Excluding Paxlovid and Comirnaty, company revenues grew only about 1% operationally, underscoring how dependent the quarter's growth was on COVID-19 products. Several legacy franchises declined sharply, including Chantix (down 99% due to a global shipment pause over nitrosamine levels), Sutent (down 47%), and Xeljanz in the U.S. (down 35%). Management raised full-year 2022 operational guidance for revenues by about $2 billion and for Adjusted diluted EPS by $0.24. After unfavorable foreign exchange, reported revenue guidance was unchanged at $98.0 to $102.0 billion, and the low end of Adjusted EPS guidance rose $0.05 to a range of $6.30 to $6.45. Guidance for Adjusted SI&A expenses was cut by $300 million, while Adjusted R&D guidance rose by $250 million, reflecting investment in mRNA and other programs. Pfizer also disclosed a pending acquisition of Biohaven that will require roughly $13.3 billion in upfront capital, with closing expected in early 2023. Investors should weigh strong near-term COVID-driven earnings against the expected decline of these revenues as the pandemic subsides and the company's large pending capital commitments. Accounting policy changes made in Q1 2022 also affect comparability. Acquired IPR&D expenses are now included in Adjusted results, and all amortization of intangibles is excluded. Prior periods were restated, so Adjusted EPS comparisons should be read with these changes in mind.

Jul 28, 2022 8-K

PFIZER INC 8-K Report, Regulation FD Disclosure (May 10, 2022)

On May 9, 2022, Pfizer agreed to acquire Biohaven Pharmaceutical Holding Company through a merger in which a Pfizer subsidiary will merge into Biohaven, which will survive as a wholly owned Pfizer subsidiary. Biohaven shareholders will receive $148.50 in cash per share, a premium of about 33% to Biohaven's $111.70 three-month VWAP before the announcement, plus 0.5 shares of a spun-off company ('New Biohaven') per share. The press release puts total cash consideration at roughly $11.6 billion. Pfizer also plans to pay about $1.26 billion at closing to retire Biohaven's credit facility and redeem its preferred shares. Pfizer expects to fund the deal with existing cash. The strategic core is Biohaven's CGRP migraine franchise. Pfizer will acquire NURTEC ODT (rimegepant), which is approved in the U.S. for acute and preventive migraine treatment and was cited as the number-one prescribed drug in its class, with cumulative U.S. net revenue of about $650 million since launch. The package also includes zavegepant, with an intranasal NDA for acute migraine, which Biohaven says it submitted in March 2022 and which is expected to be accepted in the second quarter of 2022, and five preclinical CGRP assets. Pfizer already holds a stake in Biohaven from a November 2021 collaboration that covered ex-U.S. commercialization of these products, in which it invested $350 million for 2.6% of the company at $173 per share. The closing is conditional on completing the spin-off of New Biohaven, which will hold Biohaven's non-CGRP pipeline and be capitalized with $275 million in cash. New Biohaven will also receive tiered royalties on U.S. net sales of rimegepant and zavegepant above $5.25 billion per year. Closing also requires regulatory approvals and Biohaven shareholder approval. The filing gives a fourth-quarter 2022 closing target, while the press release says 'early 2023', so investors should treat the timing as an estimate. Pfizer's deal-level disclosures do not quantify revenue or earnings contribution, so the financial impact on Pfizer's results cannot be assessed from this filing alone.

May 10, 2022 8-K

PFIZER INC 8-K Report, Financial Results (May 3, 2022)

Pfizer reported first-quarter 2022 revenues of $25.7 billion, up 77% reported and 82% operationally, driven overwhelmingly by COVID-19 products. Comirnaty contributed $13.2 billion in direct sales and alliance revenues and Paxlovid contributed $1.5 billion. Excluding Comirnaty and Paxlovid, operational revenue grew only 2%, and would have grown 5% without a 2% drag from patent losses and a 1% drag from fewer selling days. Reported diluted EPS was $1.37 and adjusted diluted EPS was $1.62, up 72% on an adjusted basis, though both figures absorb a $0.05 hit from acquired in-process R&D that Pfizer now includes in adjusted results. Chantix (down 99% due to a global shipment pause) and Xeljanz (down 29%) were notable underlying weak spots. Management reaffirmed full-year 2022 revenue guidance of $98.0 to $102.0 billion, including roughly $32 billion for Comirnaty and $22 billion for Paxlovid, despite about $2 billion of unfavorable FX. Full-year adjusted diluted EPS guidance was lowered to $6.25 to $6.45 from $6.35 to $6.55, solely due to the accounting policy change to include all acquired IPR&D expense, partly offset by operational gains and offset by an additional $0.11 FX headwind. Pfizer also repurchased $2.0 billion of stock in March at $51.10 per share, returned $4.2 billion to shareholders in the quarter, and noted that current guidance assumes no further buybacks in 2022. Investors should note that the guidance raise to R&D spending and the accounting change reduce comparability with prior periods, and that the company's revenue outlook depends heavily on COVID-19 product demand. Other developments include the Arena Pharmaceuticals acquisition (closed March 2022 for $6.6 billion), the announced departure of CFO Frank D'Amelio with David Denton succeeding him effective May 2, 2022, a failed Phase 3 primary endpoint for the C. difficile vaccine, and a non-significant Paxlovid post-exposure prophylaxis trial result.

May 3, 2022 8-K

PFIZER INC 8-K Report, Shareholder Vote Results (May 2, 2022)

Pfizer Inc. filed an 8-K report on May 2, 2022, detailing the results of its Annual Meeting of Shareholders held on April 28, 2022. The meeting primarily focused on shareholder voting on key corporate matters, including the election of directors, ratification of the independent auditor, and executive compensation. All director nominees presented were overwhelmingly elected. Additionally, shareholders approved the appointment of KPMG LLP as the company's independent registered public accounting firm for the 2022 fiscal year and, on an advisory basis, the compensation of the company's Named Executive Officers. The filing also shows that several shareholder proposals were voted upon and not approved. These proposals covered topics such as amending proxy access, reporting on political expenditures, intellectual property transfer related to COVID-19 manufacturers, board oversight of anti-competitive practices, and public health costs associated with vaccine technology. The strong support for director elections, auditor ratification, and executive compensation indicates shareholder confidence in the current leadership and financial oversight, while the rejection of shareholder proposals suggests a divergence of views on specific governance and operational initiatives.

May 2, 2022 8-K

Earnings & Results

PFIZER INC 8-K Report, Financial Results (Apr 20, 2022)

This 8-K filing from Pfizer Inc. (PFE), dated April 20, 2022, primarily announces a change in how the company calculates its non-GAAP Adjusted income and Adjusted diluted EPS, effective the first quarter of 2022. Specifically, Pfizer will now include all acquired in-process research and development (IPR&D) costs, including those from collaboration and in-license agreements, and asset acquisitions of IPR&D, in its non-GAAP adjusted results. This change is being made after consultation with the SEC staff. The company anticipates this change will reduce its Adjusted income by approximately $275 million and Adjusted diluted EPS by $0.05 for the first quarter of 2022. Pfizer also stated that it will report IPR&D expenses as a separate line item in its financial statements and will recast prior periods to conform to this new presentation. Full-year financial guidance will also begin to incorporate the impact of acquired IPR&D expenses incurred or signed through a defined date.

Apr 20, 2022 8-K